Najit Technologies, Inc.

This early-stage trial tested a new inactivated yellow fever vaccine called HydroVax-002 YFV in 26 healthy adults aged 18 to 49. Participants received two shots 29 days apart at either a low or high dose, or a placebo. The main goal was to see if the vaccine is safe and to measur…